

NAMS 14476:2024

First Edition

EN 14476:2013+A2:2019

NAMIBIAN STANDARD

Chemical disinfectants and antiseptics — Quantitative suspension test for the evaluation of virucidal activity in the medical area — Test method and requirements (Phase 2/Step 1)

This Namibian standard is the identical adoption of EN 14476:2013+A2:2019 and is adopted with the permission of the European Committee for Standardization

Published by the Namibian Standards Institution (NSI)
Established by section 2 of the Standards Act, 2005 (Act No 18 of 2005)
37 Feld Street
P.O. Box 26364 Windhoek, Namibia
Tel +264-61386400, Fax +264-61-386454
Website: www.nsi.com.na
© NSI



NAMS 14476:2024

First Edition

EN 14476:2013+A2:2019

National foreword

This Namibian Standard (NAMS) is identical to EN 14476:2013+A2:2019, and was approved for adoptions by the Namibian Standards Institution CEO.

Namibian standards are developed based on NSI Standards development procedures in accordance with the rules given in the International Organisation for Standardisation/ International Electrotechnical Commission (ISO/IEC) Directives 1, ISO/IEC Guide 21-1 Adoption of international standards as regional or national standards and WTO – TBT World Trade Organisation code of Good Practice (which is published as Annex 3 in the TBT Agreement)

The NSI Technical Committee responsible for this standard is NSI TC 14, Chemicals.

This NAMS 14476:2024 EN 14476:2013+A2:2019 was published in May 2024.

ICS 11.080.20

English Version

Chemical disinfectants and antiseptics - Quantitative suspension test for the evaluation of virucidal activity in the medical area - Test method and requirements (Phase 2/Step 1)

Antiseptiques et désinfectants chimiques - Essai quantitatif de suspension pour l'évaluation de l'activité virucide dans le domaine médical - Méthode d'essai et prescriptions (Phase 2/Étape 1)

Chemische Desinfektionsmittel und Antiseptika - Quantitativer Suspensionsversuch zur Bestimmung der viruziden Wirkung im humanmedizinischen Bereich - Prüfverfahren und Anforderungen (Phase 2, Stufe 1)

This European Standard was approved by CEN on 27 July 2015 and includes Amendment 2 approved by CEN on 9 April 2019.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

| Contents | Page |
|--|-------------|
| European foreword..... | 4 |
| Introduction | 6 |
| 1 Scope..... | 7 |
| 2 Normative references..... | 7 |
| 3 Terms and definitions | 7 |
| 4 Requirements | 8 |
| 5 Test methods | 10 |
| 5.1 Principle | 10 |
| 5.2 Materials and reagents, including cell cultures | 10 |
| 5.2.1 Test organisms..... | 10 |
| 5.2.2 Culture media, reagents and cell cultures..... | 11 |
| 5.3 Apparatus and glassware | 14 |
| 5.4 Preparation of test organism suspensions and product test solutions..... | 15 |
| 5.4.1 Test organisms suspensions (test virus suspension) | 15 |
| 5.4.2 Product test solutions..... | 16 |
| 5.5 Procedure for assessing the virucidal activity of the product..... | 16 |
| 5.5.1 General..... | 16 |
| 5.5.2 Test procedure..... | 17 |
| 5.5.3 Modified method for ready-to-use products..... | 18 |
| 5.5.4 Cytotoxicity caused by product test solutions..... | 19 |
| 5.5.5 Control of efficiency of suppression of product's activity | 20 |
| 5.5.6 Reference test for virus inactivation..... | 20 |
| 5.5.7 Titration of the virus control | 21 |
| 5.5.8 Titration of test samples..... | 21 |
| 5.6 Experimental data and calculation..... | 21 |
| 5.6.1 Protocol of results..... | 21 |
| 5.6.2 Calculation of infectivity titer (TCID ₅₀ or PFU)..... | 21 |
| 5.7 Verification of the methodology | 21 |
| 5.8 Expression of results..... | 22 |
| 5.8.1 General..... | 22 |
| 5.8.2 Calculation of the virucidal activity of products..... | 22 |
| 5.9 Test report..... | 22 |
| Annex A (informative) Examples of viruses sorted according to their presence in the human body in case of virus infection..... | 25 |
| Annex B (informative) Detoxification of test mixtures by molecular sieving..... | 27 |
| B.1 Molecular sieving with Sephadex™ LH 20 | 27 |
| B.1.1 Principle | 27 |
| B.1.2 Sephadex suspension..... | 27 |
| B.1.3 Procedure..... | 27 |
| B.2 Molecular sieving using MicroSpin™ S 400 HR..... | 29 |
| Annex C (informative) Calculation of the viral infectivity titre | 32 |
| C.1 Quantal tests — Example of TCID ₅₀ determination by the Spearman-Kärber method..... | 32 |

| | | |
|---------------------|--|-----------|
| C.2 | Plaque test..... | 33 |
| C.3 | Biometrical evaluation of experimental approaches and assessment of the disinfecting effect on the virus (reduction [R]): | 33 |
| C.3.1 | General | 33 |
| C.3.2 | Calculating the virus titre with 95 % confidence interval | 34 |
| C.3.3 | Calculating the reduction and its 95 % confidence interval | 34 |
| C.3.4 | Calculating the average reduction ($R_{(mi)}$) and its 95 % confidence interval. | 35 |
| C.3.5 | Practical example | 36 |
| Annex D | (informative) Presentation of test results of one active concentration | 38 |
| Annex E | (informative) Quantitative determination of formaldehyde concentrations..... | 41 |
| Annex ZA | (informative) $\overline{A_1}$ Relationship between this European Standard and the Essential Requirements of EU Directive 93/42/EEC..... | 42 |
| Bibliography | | 43 |

European foreword

This document (EN 14476:2013+A2:2019) has been prepared by Technical Committee CEN/TC 216 “Chemical disinfectants and antiseptics”, the secretariat of which is held by AFNOR.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by ^{A2} January 2020 ^{A2} and conflicting national standards shall be withdrawn at the latest by ^{A2} January 2020 ^{A2}.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN [and/or CENELEC] shall not be held responsible for identifying any or all such patent rights.

This document supersedes ^{A2} EN 14476:2013+A1:2015 ^{A2}.

This document includes Amendment 1 approved by CEN on 2015-07-27 and Amendment 2 approved by CEN on 2019-04-09.

The start and finish of text introduced or altered by amendment 1 is indicated in the text by tags ^{A1} ^{A1}.

The start and finish of text introduced or altered by amendment 2 is indicated in the text by tags ^{A2} ^{A2}.

^{A1} This document has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association, and supports essential requirements of EU Directive(s).

For relationship with EU Directive(s), see informative Annex ZA, which is an integral part of this document. ^{A1}

The document was revised to adapt it to the latest state of science, to correct errors and ambiguities, to harmonise the structure and wording with other existing tests of CEN/TC 216 or in preparation and to improve the readability of the standard and thereby make it more understandable. The following list is a list of significant technical changes since the last edition:

- The scope was expanded for the following fields of application within the medical area, i.e. products for textile disinfection.
- “Obligatory test conditions” were replaced by “minimum test conditions” (test temperatures and contact times can be chosen within limits) that have to be performed to pass the test.
- An additional modified method is described to test ready-to-use products in a higher concentration than 80 %, i.e. 97 %;

^{A1}

- For the hygienic handrub and handwash method a test for virucidal activity against enveloped viruses with *Vacciniavirus* was added.
- The relationship between this European Standard and the MDD was added (Foreword and Annex ZA).
- The value of v_n in C.1 was corrected (0,001 instead of 0,0001). ^{A1}

- A₂ • For the surface disinfection a test for virucidal activity against enveloped viruses with vaccinia virus was added and a test for limited spectrum virucidal activity with adenovirus and murine norovirus was added;
- The spelling of Vaccinavirus is corrected to vaccinia virus (Table 1);
- The limited spectrum virucidal activity will cover norovirus, rotavirus and adenovirus;
- The vaccinia virus strain Elstree was added as alternative strain [5.2.1c)1)], [5.5.1.1.e)];
- For dirty conditions (5.2.2.8.3) the resuspension shall be done in PBS and not in water (editorial change reflecting the actual practice);
- the dilution in ice-cold medium for the control of efficiency of suppression of products activity (5.5.5.1) was clarified;
- addition of the large-volume-plating method (5.5.4.3, B.3) A₂

A₂ The changes mentioned above have no impact on the test results obtained with reference to the previous version. Those results are still valid. A₂

Other methods to evaluate the efficacy of chemical disinfectants and antiseptics for different applications in the medical area are in preparation.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

Introduction

This document specifies a suspension test for establishing whether a chemical disinfectant or an antiseptic has a virucidal activity in the area and fields described in the scope.

This laboratory test takes into account practical conditions of application of the product including contact time, temperature, test organisms and interfering substances, i.e. conditions which may influence its action in practical situations. Each utilisation concentration of the chemical disinfectant or antiseptic found by this test corresponds to the chosen experimental conditions.